Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Single-Arm Clinical Study of Retlirafusp Alfa Combined With Apatinib and Chemotherapy as Second-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer

NCT07773363 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT07773363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07773363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Single-Arm Clinical Study of Retlirafusp Alfa Combined With Apatinib and Chemotherapy as Second-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer
Lead sponsor
Tang-Du Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 30, 2026
Completion date
December 30, 2028
Enrollment
37 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer